Literature DB >> 31814149

Dosing of Continuous Fentanyl Infusions in Obese Children: A Population Pharmacokinetic Analysis.

Anil R Maharaj1, Huali Wu1, Kanecia O Zimmerman1,2, David G Speicher3, Janice E Sullivan4, Kevin Watt1,2, Amira Al-Uzri5, Elizabeth H Payne6, Jinson Erinjeri6, Susan Lin6, Barrie Harper1, Chiara Melloni1, Christoph P Hornik1,2.   

Abstract

Differences in fentanyl pharmacokinetics (PK) between obese and nonobese adults have previously been reported; however, the impact of childhood obesity on fentanyl PK is relatively unknown. We developed a population pharmacokinetic (PopPK) model using opportunistically collected samples from a cohort of predominately obese children receiving fentanyl per the standard of care. Using a probability-based approach, we evaluated the ability of different continuous infusion strategies to provide steady-state concentrations (Css ) within an analgesic concentration range (1-3 ng/mL). Fifty-three samples from 32 children were used for PopPK model development. Median (range) age and body weight of study participants were 13 years (2-19 years) and 52 kg (16-164 kg), respectively. The majority of children (94%) were obese. A 2-compartment model allometrically scaled by total body weight provided an appropriate fit to the data. Estimated typical clearance was 32.5 L/h (scaled to 70 kg). A fixed dose rate infusion of 1 µg/kg/h was associated with probabilities between 49% and 58% for achieving Css within target; however, the risk of achieving Css > 3 ng/mL increased with increasing body weight (15% at 16 kg vs 43% at 164 kg). A proposed model-based infusion strategy maintained consistent probabilities across the examined weight range for achieving Css within (58%) and above (20%) target. Use of an allometric relationship between weight and clearance was appropriate for describing the PK of intravenous fentanyl in our cohort of predominately obese children. Our proposed model-derived continuous infusion strategy maximized the probability of achieving target Css in children of varying weights.
© 2019, The American College of Clinical Pharmacology.

Entities:  

Keywords:  dosing; fentanyl; obesity; pediatric; population pharmacokinetics

Year:  2019        PMID: 31814149      PMCID: PMC7591270          DOI: 10.1002/jcph.1562

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   2.860


  37 in total

1.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Comput Methods Programs Biomed       Date:  1999-01       Impact factor: 5.428

2.  Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.

Authors:  Ron J Keizer; Michel van Benten; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Comput Methods Programs Biomed       Date:  2010-06-02       Impact factor: 5.428

3.  Estimation of lean body mass in children.

Authors:  A M Peters; H L R Snelling; D M Glass; N J Bird
Journal:  Br J Anaesth       Date:  2011-05       Impact factor: 9.166

4.  Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases.

Authors:  Ming Jin; Susan B Gock; Paul J Jannetto; Jeffrey M Jentzen; Steven H Wong
Journal:  J Anal Toxicol       Date:  2005-10       Impact factor: 3.367

Review 5.  A review of the use of fentanyl analgesia in the management of acute pain in adults.

Authors:  P W Peng; A N Sandler
Journal:  Anesthesiology       Date:  1999-02       Impact factor: 7.892

6.  LC-MS determination of fentanyl in human serum and application to a fentanyl transdermal delivery pharmacokinetic study.

Authors:  Mingming Yu; Inas A Abdallah; Soo Hyeon Shin; Dana C Hammell; Audra L Stinchcomb; Hazem E Hassan
Journal:  Bioanalysis       Date:  2017-09-15       Impact factor: 2.681

7.  Determination of fentanyl in human plasma and fentanyl and norfentanyl in human urine using LC-MS/MS.

Authors:  N-H Huynh; N Tyrefors; L Ekman; M Johansson
Journal:  J Pharm Biomed Anal       Date:  2005-04-29       Impact factor: 3.935

8.  Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients.

Authors:  K Shibutani; M A Inchiosa; K Sawada; M Bairamian
Journal:  Br J Anaesth       Date:  2005-07-15       Impact factor: 9.166

9.  Comparative pharmacokinetics of fentanyl and alfentanil.

Authors:  S Bower; C J Hull
Journal:  Br J Anaesth       Date:  1982-08       Impact factor: 9.166

10.  Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.

Authors:  D R Mould; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-17
View more
  4 in total

Review 1.  Pharmacokinetic Pharmacodynamic Modelling Contributions to Improve Paediatric Anaesthesia Practice.

Authors:  James D Morse; Luis Ignacio Cortinez; Brian J Anderson
Journal:  J Clin Med       Date:  2022-05-26       Impact factor: 4.964

2.  Use of physiologically-based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity.

Authors:  Jacqueline G Gerhart; Fernando O Carreño; Jennifer L Ford; Andrea N Edginton; Eliana M Perrin; Kevin M Watt; William J Muller; Andrew M Atz; Amira Al-Uzri; Paula Delmore; Daniel Gonzalez
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-05-02

3.  Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population.

Authors:  Michael L Williams; Prince J Kannankeril; Joseph H Breeyear; Todd L Edwards; Sara L Van Driest; Leena Choi
Journal:  Clin Pharmacol Ther       Date:  2022-01-03       Impact factor: 6.903

Review 4.  Characterizing Pharmacokinetics in Children With Obesity-Physiological, Drug, Patient, and Methodological Considerations.

Authors:  Jacqueline G Gerhart; Stephen Balevic; Jaydeep Sinha; Eliana M Perrin; Jian Wang; Andrea N Edginton; Daniel Gonzalez
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.